Aurobindo Pharma USA Secures FTC Approval to Acquire Lannett Company

What Aurobindo Pharma announced

Aurobindo Pharma Limited informed the stock exchanges on 22 June 2026 that its U.S. subsidiary, Aurobindo Pharma USA, has received approval from the United States Federal Trade Commission (FTC) to acquire Lannett Company. The press release, dated the same day, confirms that the regulatory hurdle has been cleared, allowing the parties to move toward finalising the transaction.

"Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company" – the headline of the press release filed with the exchanges.

The announcement does not provide further details on the purchase price, financing arrangements, or the expected closing date.

FTC approval details

The FTC’s clearance indicates that the agency has completed its antitrust review and does not anticipate the transaction will substantially lessen competition in the relevant pharmaceutical markets. No conditions or remedial actions were mentioned in the filing.

Transaction overview

While the filing confirms the acquisition target – Lannett Company, a U.S.-based generic drug manufacturer – it omits specifics such as:

• Total consideration payable by Aurobindo Pharma USA.
• Whether the deal is cash, stock, or a combination.
• Any earn‑out or contingent payment mechanisms.
• Expected synergies or integration plans.

The lack of disclosed financial terms suggests that the parties may be awaiting final approvals from other regulatory bodies or shareholders before releasing a full transaction summary.

Key facts at a glance

Why this matters for investors

The FTC approval removes a major regulatory obstacle, bringing the acquisition closer to completion. For shareholders, the key considerations are:

• Potential dilution or cash outflow: Since the transaction value is undisclosed, investors cannot assess the impact on the balance sheet or share capital.
• Strategic expansion: Acquiring Lannett would broaden Aurobindo’s footprint in the U.S. generic market, potentially enhancing revenue diversification.
• Further approvals: The deal may still require clearance from other U.S. authorities (e.g., the Department of Justice) and possibly shareholder consent, which could affect timing.
• Integration risk: Without disclosed integration plans, investors should monitor future communications for details on how the two businesses will be combined.

Conclusion

Aurobindo Pharma USA has cleared a critical regulatory hurdle by obtaining FTC approval for its intended acquisition of Lannett Company. While the filing confirms the regulatory success, it does not reveal the financial terms or the timeline for closing. Investors should watch for subsequent disclosures that will outline the deal’s valuation, financing, and any additional regulatory steps required before the transaction can be completed.